Compare Duke Energy Corp (DUK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Duke Energy Corp trades at $116.51 (market cap $91.10B), while State Street SPDR S&P Biotech ETF trades at $154.06 (market cap $10.11B). The key difference: Duke Energy Corp is far larger — about 9× State Street SPDR S&P Biotech ETF's market cap, and Duke Energy Corp pays a 3.71% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DUK | XBI | |
|---|---|---|
Market Cap | $91.10B | $10.11B |
Volume | 4,199,050 | 12,903,266 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $133.46 | $169.55 |
52-Week Low | $113.23 | $104.99 |
Typical Hold Time | 74 Days | 37 Days |
Enterprise Value | $183.61B | — |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.
DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
